Alembic’s generic dorzolamide hydrochloride solution approved

Alembic Pharmaceuticals’ abbreviated new drug application for dorzolamide hydrochloride ophthalmic solution USP 2% has been approved by the FDA, according to a press release.

Indicated for the treatment of elevated IOP in ocular hypertension or open-angle glaucoma patients, it is therapeutically equivalent to Trusopt ophthalmic solution 2% (Merck), the release said.

The market size for dorzolamide is estimated to be $35 million, the release said.

Alembic Pharmaceuticals’ abbreviated new drug application for dorzolamide hydrochloride ophthalmic solution USP 2% has been approved by the FDA, according to a press release.

Indicated for the treatment of elevated IOP in ocular hypertension or open-angle glaucoma patients, it is therapeutically equivalent to Trusopt ophthalmic solution 2% (Merck), the release said.

The market size for dorzolamide is estimated to be $35 million, the release said.